Makers Laboratories FY26 profit falls 78.5% on higher costs
Makers Laboratories Limited reported a 78.5% decline in consolidated net profit to ₹235.13 lakh for FY26, despite a 16.4% rise in revenue to ₹14,059.48 lakh, as total expenses increased. On a standalone basis, the company swung to a net loss of ₹171.98 lakh from a profit of ₹464.11 lakh in the previous year. The Board approved the audited financial results on May 26, 2026.
*this image is generated using AI for illustrative purposes only.
Makers Laboratories Limited reported a 78.5% decline in consolidated net profit to ₹235.13 lakh for the financial year ended March 31, 2026, compared to ₹749.07 lakh in the previous year, as total expenses rose to ₹13,115.51 lakh. The company's consolidated revenue from operations increased 16.4% to ₹14,059.48 lakh from ₹12,075.12 lakh in FY25. On a standalone basis, the entity swung to a net loss of ₹171.98 lakh for the year against a profit of ₹464.11 lakh in the prior year, while revenue grew 17.2% to ₹5,034.73 lakh.
The Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 26, 2026. N V C & Associates LLP, the statutory auditors, issued an audit report with an unmodified opinion on the financial statements. The financial results were prepared in accordance with Indian Accounting Standards (Ind-AS) and comply with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Consolidated Performance
The group's total income for FY26 stood at ₹14,230.44 lakh, an increase from ₹13,263.76 lakh in the previous year. The profit before tax for the year decreased to ₹1,114.93 lakh from ₹1,341.06 lakh. The company operates two reportable segments: Pharmaceutical and Chemical Manufacturing. The Chemical Manufacturing segment reported a profit before tax of ₹1,368.56 lakh, while the Pharmaceutical segment reported a loss before tax of ₹253.63 lakh.
| Metric (₹ in Lacs) | FY26 | FY25 |
|---|---|---|
| Revenue from Operations | 14,059.48 | 12,075.12 |
| Total Income | 14,230.44 | 13,263.76 |
| Total Expenses | 13,115.51 | 11,843.60 |
| Profit Before Tax | 1,114.93 | 1,341.06 |
| Net Profit | 235.13 | 749.07 |
Standalone Results
On a standalone basis, the company reported a total income of ₹5,094.01 lakh for FY26, down from ₹5,386.81 lakh in the previous year. Total expenses increased to ₹5,295.14 lakh from ₹4,893.95 lakh. The company noted that other income for the previous year included a profit on the sale of Property, Plant, and Equipment amounting to ₹1,010.00 lakh, making the figures not comparable. Additionally, the company evaluated the implications of the new labour code, resulting in an incremental impact of ₹10.92 lakh charged to the profit and loss statement for employee benefits.
| Metric (₹ in Lacs) | FY26 | FY25 |
|---|---|---|
| Revenue from Operations | 5,034.73 | 4,294.46 |
| Total Income | 5,094.01 | 5,386.81 |
| Total Expenses | 5,295.14 | 4,893.95 |
| Net Loss | (171.98) | 464.11 |
Financial Position
The consolidated total assets as of March 31, 2026, stood at ₹16,661.92 lakh, up from ₹14,794.82 lakh in the previous year. The company's equity attributable to shareholders of the holding company increased to ₹7,292.41 lakh from ₹7,050.59 lakh. Non-controlling interests stood at ₹4,955.23 lakh. The standalone total assets were reported at ₹7,353.73 lakh, with total equity decreasing to ₹5,443.41 lakh from ₹5,607.54 lakh.
Historical Stock Returns for Makers Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.37% | -1.77% | +12.34% | +31.71% | +0.80% | -30.11% |
What specific measures is Makers Laboratories taking to reverse the pre-tax losses in the Pharmaceutical segment?
How will the implementation of the new labour code impact operational costs and margins in the coming fiscal year?
Will the company continue to rely on the Chemical Manufacturing segment to drive profitability, or are there plans to restructure the Pharmaceutical division?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
